Holen Sie sich die Stockscreener-App
34.56
5.60%
-2.05
Handel nachbörslich:
34.00
-0.56
-1.62%
Schlusskurs vom Vortag:
$36.61
Offen:
$36.35
24-Stunden-Volumen:
1.05M
Relative Volume:
0.84
Marktkapitalisierung:
$1.69B
Einnahmen:
$140.49M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-12.54
EPS:
-2.7551
Netto-Cashflow:
$-175.90M
1W Leistung:
-6.16%
1M Leistung:
-20.53%
6M Leistung:
+61.57%
1J Leistung:
+104.13%
1-Tages-Spanne:
$34.26
$36.91
1-Wochen-Bereich:
$34.26
$39.09
52-Wochen-Spanne:
$16.36
$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
34.56 | 1.69B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-11 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2026-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
UroGen Pharma: An Emerging GARP Stock - Seeking Alpha
UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com Nigeria
UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com - Investing.com South Africa
UroGen Pharma Officer Christopher Degnan Files Rule 144 to Sell 2,202 Shares for Tax Withholding - Kalkine Media
To cover equity-award taxes, UroGen Pharma (URGN) officer proposes selling 2,202 shares. - Stock Titan
Form 4 Urogen Pharma Ltd For: 9 October By Investing.com - Investing.com Nigeria
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - uk.finance.yahoo.com
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
UroGen Pharma (URGN) Stock May Still Trade At A Discount To Sales - simplywall.st
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction By Investing.com - Investing.com India
UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction - Investing.com
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com Nigeria
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com India
UroGen Pharma general counsel sells $64,618 in shares - Investing.com India
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale - Kalkine Media
UroGen at Wells Fargo conference: launch gains and pipeline widen By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com Canada
UroGen Pharma general counsel sells $64,618 in shares - Investing.com
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com India
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com UK
Tyra Biosciences Shares Tumble 22% as Bladder Cancer Drug Misses Efficacy Benchmark - finance.biggo.com
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding - Stock Titan
UroGen Pharma advances with strong Zusduri sales and promising URGN-103 approval ahead - Pluang
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares - Investing.com
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com South Africa
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
UroGen will speak at three investor events in September - Stock Titan
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - simplywall.st
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing - Yahoo Finance
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Manipulation Risk - careplusvn.com
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - simplywall.st
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionStrong Earnings Momentum - dars.gov.et
UroGen (URGN) Quarterly Results: EPS Comes in Above Forecast; After Earnings: Shares Close 0.13% Higher for the Current SessionEarnings Decline Risk - dars.gov.et
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Urogen Pharma Ltd-Aktie (URGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Christopher Degnan | Officer |
Oct 08 '26 |
Proposed Sale |
40.70 |
2,202 |
89,621 |
0 |
| Jason Smith | Officer |
Sep 08 '26 |
Proposed Sale |
44.09 |
1,519 |
66,973 |
0 |
| Mark Schoenberg | Officer |
Sep 08 '26 |
Proposed Sale |
44.09 |
871 |
38,402 |
0 |
| Smith Jason Drew | General Counsel |
Sep 08 '26 |
Sale |
42.54 |
1,519 |
64,618 |
53,141 |
| Schoenberg Mark | Chief Medical Officer |
Sep 08 '26 |
Sale |
42.92 |
871 |
37,383 |
59,882 |
| Schoenberg Mark | Officer |
Aug 20 '26 |
Proposed Sale |
47.67 |
60,677 |
2,892,242 |
0 |
| Schoenberg Mark | Chief Medical Officer |
Aug 20 '26 |
Sale |
47.05 |
60,677 |
2,854,853 |
59,086 |
| Schoenberg Mark | Officer |
Jul 09 '26 |
Proposed Sale |
40.00 |
10,000 |
400,008 |
0 |
| Schoenberg Mark | Chief Medical Officer |
Jul 09 '26 |
Sale |
40.00 |
10,000 |
400,000 |
119,763 |
| Schoenberg Mark | Chief Medical Officer |
Jun 22 '26 |
Sale |
35.01 |
10,000 |
350,100 |
129,763 |
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):